ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are in clinical trials: VAL201 (Phase I/II) – a peptide for advanced prostate cancer and potential to treat other hormone- induced indications; and VAL401 (Phase II) – a novel reformulation of risperidone, in trials for lung cancer. Both drugs are targeted at multi-billion dollar markets that are inadequately served by current drugs. The aim is to progress the clinical data and exit via a collaboration or commercial out-licensing to a larger partner.
If you'd like to be introduced to the team at ValiRx, get in touch.Request a meeting